Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Alnylam Pharmaceuticals is one of 950 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Alnylam Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).Over the past 90 days, the Zacks Consensus Estimate for ALNY's full-year earnings has moved 326.8% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.According to our latest data, ALNY has moved about 95.7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 4.6% on a year-to-date basis. This means that Alnylam Pharmaceuticals is performing better than its sector in terms of year-to-date returns.Collegium Pharmaceutical (COLL) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 58.3%.Over the past three months, Collegium Pharmaceutical's consensus EPS estimate for the current year has increased 9.1%. The stock currently has a Zacks Rank #1 (Strong Buy).Breaking things down more, Alnylam Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 468 individual companies and currently sits at #89 in the Zacks Industry Rank. On average, this group has gained an average of 15.7% so far this year, meaning that ALNY is performing better in terms of year-to-date returns. In contrast, Collegium Pharmaceutical falls under the Medical - Drugs industry. Currently, this industry has 144 stocks and is ranked #78. Since the beginning of the year, the industry has moved +6.4%.Going forward, investors interested in Medical stocks should continue to pay close attention to Alnylam Pharmaceuticals and Collegium Pharmaceutical as they could maintain their solid performance.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks